» Articles » PMID: 28699521

Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy

Overview
Journal Curr Pharm Des
Date 2017 Jul 13
PMID 28699521
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a devastating neurological illness with a heavy economic impact. Further comorbidities in combination with the social impact of this disorder increase the urgency of a clearer comprehension of its etiopathogenesis, allowing the execution of novel therapeutic strategies. Despite astrocytes have been widely described as active participant in the regulation of cerebral circuits, available data are still poor. Even less information is available about their precise role in the pathogenesis of illness. Moreover, the scant knowledge about the astrocyte-neuron interplay in health and disease still impedes pioneering discoveries. The focus of this review is to look for new and innovative pharmacological approaches against AD. In order to perform this, we used the following keywords in PubMed search engine: astrocytes, therapy, Alzheimer's disease, and glia in different combinations. With this review, we collected data available in literature describing how also astrocytes besides neurons might be new potential targets for drug discovery. Different approaches currently being studied include modulation of glutamate transporters expression, astroglial genetic manipulation, free radicals inhibition, up-regulation of neurotrophins, and regulation of astrogliosis and neuroinflammation. Since several studies already demonstrated that astrocytes are definitely involved in AD pathogenesis, these cells can represent a promising new therapeutic target.

Citing Articles

Search for unknown neural link between the masticatory and cognitive brain systems to clarify the involvement of its impairment in the pathogenesis of Alzheimer's disease.

Kang Y, Toyoda H, Saito M Front Cell Neurosci. 2024; 18:1425645.

PMID: 38994328 PMC: 11236757. DOI: 10.3389/fncel.2024.1425645.


The role and potential therapeutic targets of astrocytes in central nervous system demyelinating diseases.

Tan R, Hong R, Sui C, Yang D, Tian H, Zhu T Front Cell Neurosci. 2023; 17:1233762.

PMID: 37720543 PMC: 10502347. DOI: 10.3389/fncel.2023.1233762.


Structural characterization and anti-oxidation activity evaluation of pectin from Thunb.

Qi X, Yu Y, Wang X, Xu J, Wang X, Feng Z Front Nutr. 2022; 9:998462.

PMID: 36204375 PMC: 9530389. DOI: 10.3389/fnut.2022.998462.


Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer's Disease.

Facchinetti R, Valenza M, Gomiero C, Mancini G, Steardo L, Campolongo P Biomedicines. 2022; 10(6).

PMID: 35740258 PMC: 9219769. DOI: 10.3390/biomedicines10061236.


Overproduction of hydrogen sulfide, generated by cystathionine β-synthase, disrupts brain wave patterns and contributes to neurobehavioral dysfunction in a rat model of down syndrome.

Panagaki T, Lozano-Montes L, Janickova L, Zuhra K, Szabo M, Majtan T Redox Biol. 2022; 51:102233.

PMID: 35042677 PMC: 9039679. DOI: 10.1016/j.redox.2022.102233.